Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm

What’s a pharma company to do when another drugmaker poaches 19 of its salespeople in preparation for launching a rival product? Many companies would buckle down, hire even more qualified salespeople and prop up the marketing message to make it clear to physicians why they should choose the first-to-market product.